Monday, April 17, 2017
M3 Biotechnology Gets $1.4M
Seattle-based M3 Biotechnology, a company which is developing small molecule therapeutics aimed at Alzheimer's treatment, has raised $1.4M in a Series B funding, the company said Monday. The funding came from Dolby Family Ventures and the Alzheimer's Drug Discovery Foundation. M3's CEO is Leen Kawas.